Chagas Disease (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chagas Disease – Drugs In Development, 2021, provides an overview of the Chagas Disease (Infectious Disease) pipeline landscape.

Chagas disease or American Trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting and swollen glands. Treatment includes antiparasitic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Chagas Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 2, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 5 molecules, respectively.

Chagas Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Chagas Disease (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Chagas Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Chagas Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Chagas Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Chagas Disease (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Chagas Disease (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Chagas Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AstraZeneca Plc

Cesa Alliance SA

Collaborations Pharmaceuticals Inc

ConserV Bioscience Ltd

Daiichi Sankyo Co Ltd

Diakonos Research Ltd

Eisai Co Ltd

GlaxoSmithKline Plc

IC-MedTech Inc

Novartis AG

Oblita Therapeutics BVBA

Sanofi

Selva Therapeutics Inc

Synstar Japan Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chagas Disease (American Trypanosomiasis) - Overview

Chagas Disease (American Trypanosomiasis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Cesa Alliance SA

Collaborations Pharmaceuticals Inc

ConserV Bioscience Ltd

Daiichi Sankyo Co Ltd

Diakonos Research Ltd

Eisai Co Ltd

GlaxoSmithKline Plc

IC-MedTech Inc

Novartis AG

Oblita Therapeutics BVBA

Sanofi

Selva Therapeutics Inc

Synstar Japan Co Ltd

Chagas Disease (American Trypanosomiasis) - Drug Profiles

(benznidazole + pyronaridine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(sodium ascorbate + menadione sodium bisulfite) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chagas disease (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chagas disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chagas disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas disease vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cz-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cz-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNDI-0690 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexinidazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosravuconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNF-6702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAO-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyronaridine tetraphosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLV-213 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for African Trypanosomiasis and Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chagas Disease and Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Protozoal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP51A1 for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Pex14 for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VNI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chagas Disease (American Trypanosomiasis) - Dormant Projects

Chagas Disease (American Trypanosomiasis) - Discontinued Products

Chagas Disease (American Trypanosomiasis) - Product Development Milestones

Featured News & Press Releases

Jun 01, 2019: Vaccine for prevention and treatment of Trypanosoma cruzi infection

Jun 22, 2017: UTEP Scientists Awarded Patent for Chagas Disease Vaccine

Aug 08, 2016: A single compound could treat three parasitic diseases

Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease

Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy

May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world

Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease

Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Products under Development by Universities/Institutes, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by AstraZeneca Plc, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Cesa Alliance SA, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Collaborations Pharmaceuticals Inc, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by ConserV Bioscience Ltd, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Daiichi Sankyo Co Ltd, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Diakonos Research Ltd, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Eisai Co Ltd, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by GlaxoSmithKline Plc, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by IC-MedTech Inc, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Novartis AG, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Oblita Therapeutics BVBA, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Sanofi, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Selva Therapeutics Inc, 2021

Chagas Disease (American Trypanosomiasis) – Pipeline by Synstar Japan Co Ltd, 2021

Chagas Disease (American Trypanosomiasis) – Dormant Projects, 2021

Chagas Disease (American Trypanosomiasis) – Dormant Projects, 2021 (Contd..1)

Chagas Disease (American Trypanosomiasis) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Chagas Disease (American Trypanosomiasis), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports